Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients

Nathalie Eymard 1 Vitaly Volpert 2 Polina Kurbatova 3 Nikolai Bessonov 4 Kayode Ogungbenro 5 Leon Aarons 5 Perrine Janiaud 3 Patrice Nony 3 Agathe Bajard 6 Sylvie Chabaud 6 Yves Bertrand 7 Behrouz Kassaï 8 Catherine Cornu 8
1 ICJ - Institut Camille Jordan [Villeurbanne]
2 DRACULA - Multi-scale modelling of cell dynamics : application to hematopoiesis
CGMC - Centre de génétique moléculaire et cellulaire, Inria Grenoble - Rhône-Alpes, ICJ - Institut Camille Jordan [Villeurbanne], UCBL - Université Claude Bernard Lyon 1 : EA
3 LBBE - Laboratoire de Biométrie et Biologie Evolutive
4 Institute of Mechanical Engineering Problems
5 Centre for Applied Pharmacokinetic Research
6 UBET - Unité de Biostatistique et d'Evaluation des Thérapeutiques
7 ICMUB - Institut de Chimie Moléculaire de l'Université de Bourgogne [Dijon]
8 CIC Lyon
Abstract : T lymphoblastic lymphoma (T-LBL) is a rare type of lymphoma with a good prognosis with a remission rate of 85%. Patients can be completely cured or can relapse during or after a 2-year treatment. Relapses usually occur early after the remission of the acute phase. The median time of relapse is equal to 1 year, after the occurrence of complete remission (range 0.2–5.9 years) (Uyttebroeck et al., 2008). It can be assumed that patients may be treated longer than necessary with undue toxicity. The aim of our model was to investigate whether the duration of the maintenance therapy could be reduced without increasing the risk of relapses and to determine the minimum treatment duration that could be tested in a future clinical trial. We developed a mathematical model of virtual patients with T-LBL in order to obtain a proportion of virtual relapses close to the one observed in the real population of patients from the EuroLB database. Our simulations reproduced a 2-year follow-up required to study the onset of the disease, the treatment of the acute phase and the maintenance treatment phase.
Keywords : thymus randomized controlled clinical trial cancer T-cell lymphoblastic lymphoma mathematical modelling chemotherapy
Type de document :
Article dans une revue
Mathematical Medicine and Biology, Oxford University Press (OUP), 2017, 〈10.1093/imammb/dqw019〉
Liste complète des métadonnées

Littérature citée [41 références]  Voir  Masquer  Télécharger
https://hal.archives-ouvertes.fr/hal-01568372
Contributeur : Vitaly Volpert <>
Soumis le : mardi 25 juillet 2017 - 11:39:51
Dernière modification le : lundi 28 août 2017 - 15:12:47

Fichier

dqw019.pdf
Fichiers produits par l'(les) auteur(s)

Identifiants

Collections

EC-LYON | HCL | INSMI | TDS-MACS | CGPHIMC | BIOENVIS | UNIV-ST-ETIENNE | INC-CNRS | INRIA | ICMUB | ICJ

Citation

Nathalie Eymard, Vitaly Volpert, Polina Kurbatova, Nikolai Bessonov, Kayode Ogungbenro, et al.. Mathematical model of T-cell lymphoblastic lymphoma: disease, treatment, cure or relapse of a virtual cohort of patients. Mathematical Medicine and Biology, Oxford University Press (OUP), 2017, 〈10.1093/imammb/dqw019〉. 〈hal-01568372〉

Exporter

BibTeX TEI DC DCterms EndNote
Rdf

Partager

Métriques

Consultations de
la notice

156

Téléchargements du document

28

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD